Biotech in Brasil Cluster Minas Gerais. V Seminário de Negócios



Similar documents
Belo Horizonte and Rio de Janeiro, October 15th 2015

The Healthcare market in Brazil

Federal University of Juiz de Fora. José Luiz R. Pereira Vice Rector

Dialogues for creating a collective platform of business cooperation between Brazil and Nigeria.

Application Form Main Exhibitor

Hong Kong Poised to be the Asia s Biotechnology Hub

UNESP s Graduate Programs: Fields of International Excellence

Institutional Presentation SEPTEMBER / 2015

Private Healthcare. How To Apply For IFC Financing About IFC CREATING OPPORTUNITY IN EMERGING MARKETS

How companies leverage quality and quality certifications to achieve competitive advantage

Carlos Sigueyuki Sediyama Universidade Federal de Viçosa Departamento de Fitotecnia Viçosa - Minas Gerais Brasil. csediyama@ufv.

The majority of pharmaceutical companies in

Brazil. Challenges in the Market

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Kazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology. Master s program.

EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success

PMBOK Guide 3 rd Edition Flow

Brazilian Healthcare Regulatory change results in investment opportunities for foreign organizations

Ministry of Development, Industry and Foreign Trade. Igor Manhães Nazareth Director of Innovation

Special Feature: Growth Model of an Agile Company

Are you interested in working in ministry for the Catholic Church in our local community?

19 October Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic By ;

Abbott Diagnostics. Durable Growth Business

KENYATTA UNIVERSITY SCHOOL OF PURE AND APPLIED SCIENCES

Biology Majors Information Session. Biology Advising Center NHB 2.606

GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)

Providing Trusted and Innovative Solutions t o the Life Science Communities

Masters Learning mode (Форма обучения)

Craig Hallum Conference Investor Presentation

Health Care Services

Profile of Biomedical Research and Biotechnology Commercialization. San Diego Metropolitan Statistical Area

Rua do Mercado 34, 17ºandar, , Rio de Janeiro, RJ, +55 (21)

MAHINDRA CIE AUTOMOTIVE

LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi

2015 FOYA Award for facility integration Multipurpose Biologics and Vaccines Production Facility. IDT Biologika 2015 FOYA Award Facility Integration

Jordan University of Science and Technology (JUST)

EXECUTIVE SEARCH, INTERIM MANAGEMENT, NON-EXECUTIVE DIRECTORS & CONSULTING

Policies and Practices of China In Commercialization of Public R&D Outputs

Welcome to the ChemCon Company Presentation: 6 Steps to Success for our Customers!

Czech Biotech. Great past, present, promising future Overall description Association CzechBio CzechBio members

University of São Paulo School of Economics, Business Administration and Accounting at Ribeirão Preto

Spain: Medical equipment and healthcare technology sector

ACC San Diego Chapter

2015 Russian Nanotechnology Investment Enabling Technology Leadership Award

The Top Logistics Hubs Panel

Trade Credit Insurance

UCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA

Healthcare Sector Development: Russia s Top Priority. Miguel Hernandez Commercial Officer U.S. Commercial Service U.S. Embassy Moscow 2014

History & Fast Facts. Academic Programs. Research & Innovation. Education

China s 12th Five-Year Plan: Healthcare sector

I. World trade developments


COMPANY OVERVIEW. Feb Fast Company Brazil All rights reserved

MEXICO AS AN AUTOMOTIVE MANUFACTURING PLATFORM FOR EXPORTING Emilio Cadena PRESIDENT & CEO

Diabetes Trends in the U.S.: Results from the National Health and Wellness Survey. White Paper. by Kathy Annunziata and Nikoletta Sternbach

Russia USA Science to Innovations Accelerator (RUSSIA) Business Development and Training Program a at Arizona State University

USP CONVENTION MEMBERS BY WORLD REGION

BENCHMARKING OF BUSINESS INCUBATORS. in the Republic of Moldova. Aurelia Braguta

CATÓLICA PORTO ECONOMICS AND MANAGEMENT. Undergraduate Graduate Executive education. Act. for your future

Curriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education

Recent Updates on European Requirements and what QPs are expected to do

partnership This study is an initiative of BRBIOTEC Brasil (the Brazilian Association of Biotechnology) within the scope of Brazilian Biotechnology

How to improve the Banco Santander Brasil business model by analyzing opportunities of Cross Sell

6. Funding Strategies for Business Incubation and Sustainability

Valentina Gualato, Ph.D. Process Development Scientist

Achievement of Korea s Healthcare Industry. Devices. World s largest market share in ultrasound imaging devices ( 14) Competitiveness

I. World trade developments


HAS BRAZIL REALLY TAKEN OFF? BRAZIL LONG-RUN ECONOMIC GROWTH AND CONVERGENCE

A Degree in Science is:

School of Economics, Business Administration and Accounting at Ribeirão Preto. University of São Paulo

US Regulations for Import and Export of Cell Therapy Products

F&R Engenheiros Consultores SC

Spinnovator Public Private Partnership for Spin-offs

Types of Project Management Offices (PMO)

Transcription:

Biotech in Brasil Cluster Minas Gerais V Seminário de Negócios

Biotechnology Brasil

Biotechnology Brasil The Brazil stands out, along with Russia, India, China and South Africa, as a major emerging country of the first decade of the 21st century. Since 1990, the country has experienced steady GDP growth of around 3% per year, with a slight dip in 2012, when growth was 0.9%. Several government institutions such as BNDES, FINEP and others have supported and invested in Brazil. The Ministry of Science, Technology and Innovation and the Ministry of Development, Industry and Foreign Trade have been very active in implementing policies of national innovation.

Biotechnology Brasil

Biotechnology Minas Gerais

Contexto Econômico Economic Context Fonte: PBH

Biotechnology Minas Gerais Minas Gerais is the second largest economy in the country, with growth rates above the national average. The Government of Minas prioritizes investments in the production and development of Minas Gerais Technology Park - making the state one of the most innovative Latin America. Government of Minas put the sector of biotechnology and life sciences as one of the main axes of work and investment. + 200 manufacturing Biotech and Life Sciences companies.

Biotechnology Minas Gerais Technological Incubators: Inova (UFMG), Habitat (Biominas), INCIT,...; Very good Universities: UFMG, Ciências Médicas, PUC Minas. Research Centers (EMBRAPA, CETEC, FUNED, FIOCRUZ/RR). Ezequiel Dias Foundation - FUNED

EZEQUIEL DIAS FOUNDATION (FUNED) State Institution linked to Minas Gerais Health Department FUNED is aligning SUS (National Health System) policies - Domestic production of drugs currently imported by the government. FUNED is a major supplier for Ministry of Health and MG for Pharma Medicines and Serum (snakes, tetanus, etc).

Policies for foreign investments Ranking Incentive for investments Policies for foreign capital Source: Unidade de Inteligência da Economist, Veja Abril (2012)

AMBIOTEC Minas Gerais Bioindustry Association

The Governance of Biotech Cluster AMBIOTEC is a Private and non-profit Association; Located in Technological Park BHTEC; Created in 2010 by biotech companies; more than 40 members manufacturers of products and services in the areas of human, animal and environment; Generate annual turnover of US$ 700 million (more than 2 billion Reais). Technologial Park Belo Horizonte - BHTEC

Business Environment Business Environment Fonte: Belotur

Cluster: Products and Services HUMAN HEALTH Molecular Diagnostics; Diagnostic kits and reagents for clinical analysis; Bone and tissue reconstruction; Injectable drugs and pharmaceuticals; Reagents for rapid tests; Production of synthetic antibodies; Proccess optimization automation equipments; Medical devices; Laboratory Control.

Cluster: Products and Services ANIMAL HEALTH AND AGRIBUSINESS Animal genetics diagnostics by DNA; Animal and plant genetic breeding; Injectable medicine. ENVIRONMENT Consulting services; Microbiological and physico-chemical tests

Companies at the Belo Horizonte area: Medical Devices Companies certified and registered at ANVISA

Opportunity in the Brazilian and South America Market

The Summary Entrepreneurs background/career Company history Company profile Products Sales activities Growing strategy Commercial projections Strengths / Company organization / Our offer Shareholders and strategic alliances Contacts

Founder and CEO of Celer Biotecnologia S/A Background/Career Mr. Denilson Laudares Rodrigues Electrical Engineering (1993) Pontifical Catholic University of MG PUC Minas MSc Mechatronics (1997) Aeronautics Technological Institute ITA Ph.D. Computer Science (2002) Federal University of MG UFMG University of Pennsylvania UPENN U.S. Part-time professor at PUC Minas

Background/Career Mr. Andreas Flugs Industrial Engineering and Management MSc Ilmenau University of Technology Germany (1998) CEO of BERATA GmbH, Altran Affiliate, Munich, Germany, (2000-2005) Senior Consultant of BeOne München GmbH, Munich, Germany, (2005-2008) COO of CELER, Brazil (2009)

Background/Career Mr. Rafael Vilarinhos Regional Sales Manager BIOBRAS (2002-2008) National Sales Manager PRODIMOL / ALERE (2008-2012) Business Administration Unopar Brazil (2012) CCO of CELER, Brazil (2012)

The Company MISSION Provide high technology in customizable solutions to optimize process to the heath sector. VISION Become the leading reference in the Latin America market as a supplier of innovative solutions to improve the human health.

History Timeline AFE and Initial Registrations Microplate Reader and Washer; Tax Benefits New Partner and Business Model Portfolio expansion and new opportunities 2008 2009 2010 2011 2012 2013 2014 2015 Invested by CRIATEC Semiautomatic Biochemistry GMP (CBPF) for instruments manufacturing New registers; GMP for Consumables; Importer and Distributer

The Company Develops and produces instruments for automation in clinical diagnosis. Multi skilled technical staff. Close connections with universities, research centers and companies in clinical diagnostics. Partner of BNDES (CRIATEC Fund) Local regulations ANVISA CBPF (GMP).

Our distribution network Distribution network Celer has a wide network of Distributors that covers all regions of Brazil. This Network includes 34 Distributors witch are attending the private market as well as the public sector and two commercial representants to serve the North and Northeast. Beside of the distribution network CELER participates direct on public tenders.

Commerce of CELER Strategy 1 Current portfolio New partner Production in house BS, EE, EV BA, EA, QL,.. Other possibilities FINAL CLIENT Laboratories International Partner Equip. + Reagents Netw. Of Dist. Lab. Research Lab. diagnostic Re-Sales 2 Agents National Partner OEM Export Distributors Service for technical assistant 3

CELER`s Strengths CBPF ANVISA certificated production system Certification of good manufacturing practices. BDNDES payment card Payments of national products/instruments with up to 48 rates. CELER is receiving the payment on time. NBC T19,41 CELER is audited once per year for good governance practices. CELER received public investment and is, because of this, always in favor of public institutions, specific in registration of products within ANVISA. With the law nr. 12.349, CELER has a major competitiveness to gain public tenders while the state has to prefer national products for public tenders.

Our offer CELER offers you OEM production at the best quality level and the Implementation with a strong R&D team (PhD and Masters). CELER operate for you a strong distribution network to serve the market of BRAZIL and SOUTH AMERICA. CELER is open for direct or indirect business participation. Familiarity with management of equipment/instruments productive processes for greater degree of complexity. Investment Fund Governmental (BNDES) Partnership, which provides differentiated treatment in all levels of government processes and opportunities for future investments.

Strategic Alliances

Contacts Denilson Laudares Rodrigues denilsonlr@celer.ind.br +55 31 9302-1082 Andreas Flugs aflugs@celer.ind.br +55 31 8429-2868 Rafael Vilarinhos Rafael.vilarinhos@celer.ind.br +55 31 9165-1308 www.celer.ind.br Rua Padre Eustáquio, 1133 subloja 11 Belo Horizonte MG ZIP 30710.580 Brazil Phone +55 31 3413-0814

Thank you! Denilson Laudares Rodrigues Conselheiro AMBIOTEC ambiotec@ambiotec.org.br www.ambiotec.org.br +55 31 3401-1125